---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-24-000018"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:13:20.847847+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q1 2024 net income $0.9M; VYJUVEK revenue $45.3M; cash $622M

## Summary
- Net income $0.9M ($0.03 EPS) vs net loss $45.3M ($1.76 loss) in Q1 2023.
- VYJUVEK net product revenue $45.3M, gross margin 95%, patient compliance 91%.
- Cash $622.3M; FY 2024 Non-GAAP R&D+SG&A guidance $150M-$175M.
- Pipeline: KB408 AATD first patient; KB407 CF Cohort 2 complete; inhaled KB707 first patient; intratumoral KB707 Cohort 3 enrolled.
- Regulatory: European MAA decision and GMP certification expected 2H 2024; Japan NDA filing target 2H 2024.

## SEC filing metadata
- accession: 0001711279-24-000018
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000018/0001711279-24-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000018/krys-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-24-000018
- JSON: https://secwatch.observer/filing/0001711279-24-000018.json
- Plain text: https://secwatch.observer/filing/0001711279-24-000018.txt

## Key facts
- Earnings Releases
  Krystal Biotech, Inc. reported the first quarter ending March 31, 2024 results: revenue $45.3 million.
  - Period: the first quarter ending March 31, 2024
  - Revenue: $45.3 million
  - Result: reported results
  source text: The Company recorded $45.3 million in VYJUVEK net product revenue for the first quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000018/0001711279-24-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.